Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Recruiting 2Terminated 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 5NET 4Gastrointestinal 3CNS 1

Conditions

Gastro-enteropancreatic neuroendocrine tumor 2Pancreatic Neoplasms 1Neuroendocrine Tumors 1Carcinoid Tumor 1Adenoma, Islet Cell 1Acromegaly 1

Interventions

Oxaliplatin 300Fluorouracil 272Gemcitabine 236Bevacizumab 235Leucovorin 211Capecitabine 207pembrolizumab 201Nivolumab 158Irinotecan 158Cisplatin 150Specimen Handling 143Magnetic Resonance Spectroscopy 129130-nm albumin-bound paclitaxel 118Paclitaxel 109durvalumab 106Cetuximab 103Radiotherapy 99Drug Therapy 94atezolizumab 93Biopsy 92tislelizumab 81Albumin-Bound Paclitaxel 81Taxes 74lenvatinib 67Folfox protocol 67Carboplatin 66regorafenib 60Blood Specimen Collection 60sintilimab 54Ipilimumab 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
lanreotide × Gastrointestinal × 1 year × Clear all
NCT06807437 2026-03-31

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

SWOG Cancer Research Network

Phase 3 Recruiting
274 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05477576 2026-03-30

ACTION-1

RayzeBio, Inc.

Phase 3 Recruiting
338 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT05364944 2025-11-17

OXTEND-01

Debiopharm International SA

Phase 1 Terminated
19 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Acromegaly

Data powered by HemOnc (CC BY 4.0) Colophon âš¡